A new article in the peer-reviewed journal Nucleic Acid Therapeutics describes the characterization of antibodies targeting ...

For at least 30 years scientists and drug developers bent on a sorely needed new class of therapeutics have been studying antisense RNA. The concept is deceptively simple: Binding of an ...

Much of the non-coding RNA is produced as the complementary strand to mRNA and is therefore referred to as antisense RNA (asRNA). Their function has been unclear for a long time.

Theoretically, PNAs can bind more strongly than most antisense drugs being developed today, which are snippets of DNA or RNA. But realizing that application was far from straightforward.

Antisense oligonucleotide rescue of CGG expansion–dependent FMR1 mis-splicing in fragile X syndrome restores FMRP. Proceedings of the National Academy of Sciences, 2023; 120 (27) DOI: 10.1073 ...

Patients receiving a kidney transplant and who are positive for BK virus (BKV) are at risk of losing their transplant due to BKV reactivation. At this time, there are no antiviral options available ...

When LINE-1 RNA was depleted in human progeroid cells using antisense oligonucleotides the senescent phenotypes were ameliorated, while in the premature aging mouse model this therapy restored tissue ...

Secarna Pharmaceuticals is the leading independent European next-generation antisense drug discovery and development company addressing high unmet medical needs in immuno-oncology and immunology ...

One way to alter RNA splicing is to create an antisense oligonucleotide (ASO), a short piece of DNA with a complementary sequence, which will bind to the target mRNA.